Takeda delivers strong revenue and profit growth in FY2022

11 May 2023

Japan’s largest drugmaker Takeda (TYO: 4502) has announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products.

Global revenues for the year were up 12.8% at 4,027 billion yen ($29.8 billion). Operating profit rose 6.4% to 490.5 billion yen, with net profit rising 37.8% to 317.0 yen. Earnings per share (EPS) increased 38.8% to 204 yen.

Christophe Weber, Takeda’s president and chief executive, commented: “FY2022 was another strong year for Takeda, reflecting successful execution against our business strategy and advancements in our innovative pipeline—enabling us to deliver truly transformative treatments to patients. Important pipeline milestones included the first approvals for our dengue vaccine Qdenga, positive late-stage readouts for TAK-755 and fazirsiran, and the acquisition of TAK-279 for immune-mediated diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK